Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Acomplia

Known as: Zimulti 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
INTRODUCTION Obesity and related cardiometabolic derangements are spiraling global health problems urgently in need of safe… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2011
2011
Acomplia was ordered over the internet resulting in the delivery of counterfeit Acomplia and imitation products. The tablets were… Expand
Is this relevant?
2009
2009
Effective prophylaxis for post-traumatic epilepsy currently does not exist, and clinical trials using anticonvulsant drugs have… Expand
Is this relevant?
Review
2008
Review
2008
The CB1 inverse agonist/antagonist SR141716A recently has been introduced for the management of obesity (rimonabant; Acomplia… Expand
Is this relevant?
Highly Cited
2007
Highly Cited
2007
BACKGROUND AND PURPOSE Rimonabant (Acomplia, SR141716A), a cannabinoid CB1 receptor inverse agonist, has recently been approved… Expand
Is this relevant?
2007
2007
A meta-analysis of all randomised controlled trials examining the efficacy and safety of the anti-obesity agent Rimonabant… Expand
Is this relevant?
Review
2006
Review
2006
Rimonabant (SR141716, Acomplia) has been described as an antagonist/inverse agonist at the cannabinoid receptor type 1 (CB1). It… Expand
Is this relevant?
Highly Cited
2005
Highly Cited
2005
It is well established that Cannabis sativa can increase appetite, particularly for sweet and palatable foods. In laboratory… Expand
Is this relevant?
Review
2005
Review
2005
Over past centuries, Cannabis sativa (Delta(9)-tetrahydrocannabinol being the principal active ingredient) has been used… Expand
Is this relevant?
Review
2005
Review
2005
The endocannabinoid system plays a major role in the regulation of body energy by stimulation of the appetite in the hypothalamus… Expand
Is this relevant?